文献速递冠心病心力衰竭与心肌病

神经肽Y导致冠状动脉微血管收缩并与ST段抬高型心肌梗死后射血分数降低相关

Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.
PubMed 文献 · Eur Heart J · 2019-01-01

研究探讨了神经肽Y(NPY)在ST段抬高型心肌梗死(STEMI)后对冠状动脉微血管的影响。结果显示,STEMI患者外周静脉NPY水平显著高于急性冠脉综合征/稳定型心绞痛或冠状动脉正常者,冠状窦与外周NPY水平正相关。冠状窦NPY水平最高的STEMI患者冠脉血流储备更低、微血管阻力指数更高,2天后心肌水肿和微血管阻塞更严重,6个月后射血分数更低、心室扩张更明显。NPY通过Y1受体引起大鼠微血管收缩,Y1受体拮抗剂可阻断该效应。

要点

  • STEMI患者外周静脉NPY水平显著高于急性冠脉综合征/稳定型心绞痛及冠状动脉正常者。
  • 再灌注后冠状窦NPY水平高与微血管功能障碍、心肌损伤及6个月射血分数降低相关。
  • NPY通过Y1受体收缩冠状动脉微血管,Y1受体拮抗剂可能作为PPCI辅助治疗。

核心结论

  • 再灌注后高冠状窦NPY水平与微血管功能障碍、更严重心肌损伤及STEMI后6个月射血分数降低相关。
  • NPY通过Y1受体收缩冠状动脉微循环,拮抗剂可能是有用的PPCI辅助治疗。

研究设计与样本

  • 研究纳入STEMI患者45例、急性冠脉综合征/稳定型心绞痛患者48例及冠状动脉正常者16例,测定外周静脉和冠状窦NPY水平。
  • 使用冠状动脉血流导丝测量冠脉血流储备和微血管阻力指数,心脏磁共振评估心肌水肿和微血管阻塞,随访6个月评估射血分数和心室扩张。
  • 大鼠微血管冠状动脉和Langendorff心脏实验评估NPY的血管收缩效应及Y1受体拮抗剂BIBO3304的作用。

主要发现

  • STEMI患者外周静脉NPY水平显著高于急性冠脉综合征/稳定型心绞痛或冠状动脉正常者。
  • 整体冠状窦与外周静脉NPY水平呈显著正相关(r=0.79)。
  • 冠状窦NPY水平最高的STEMI患者冠脉血流储备显著更低,微血管阻力指数更高。
  • 上述患者2天后心肌水肿和微血管阻塞显著更严重,6个月后射血分数显著更低且心室扩张。
  • NPY(100-250 nM)通过增加血管平滑肌钙波引起大鼠微血管冠状动脉显著收缩,并增加Langendorff心脏冠状血管阻力和梗死面积,该效应可被Y1受体拮抗剂BIBO3304(1 μM)阻断;人冠状动脉微血管免疫组化显示血管平滑肌存在Y1受体。

临床怎么用

  • 再灌注后冠状窦NPY水平可能有助于识别微血管功能障碍和心肌损伤高风险STEMI患者。
  • Y1受体拮抗剂可能作为PPCI辅助治疗以减轻NPY介导的微血管收缩,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The co-transmitter neuropeptide-Y (NPY) is released during high sympathetic drive, including ST-elevation myocardial infarction (STEMI), and can be a potent vasoconstrictor. We hypothesized that myocardial NPY levels correlate with reperfusion and subsequent recovery following primary percutaneous coronary intervention (PPCI), and sought to determine if and how NPY constricts the coronary microvasculature. METHODS AND RESULTS: Peripheral venous NPY levels were significantly higher in patients with STEMI (n = 45) compared to acute coronary syndromes/stable angina ( n = 48) or with normal coronary arteries (NC, n = 16). Overall coronary sinus (CS) and peripheral venous NPY levels were significantly positively correlated (r = 0.79). STEMI patients with the highest CS NPY levels had significantly lower coronary flow reserve, and higher index of microvascular resistance measured with a coronary flow wire. After 2 days they also had significantly higher levels of myocardial oedema and microvascular obstruction on cardiac magnetic resonance imaging, and significantly lower ejection fractions and ventricular dilatation 6 months later. NPY (100-250 nM) caused significant vasoconstriction of rat microvascular coronary arteries via increasing vascular smooth muscle calcium waves, and also significantly increased coronary vascular resistance and infarct size in Langendorff hearts. These effects were blocked by the Y1 receptor antagonist BIBO3304 (1 μM). Immunohistochemistry of the human coronary microvasculature demonstrated the presence of vascular smooth muscle Y1 receptors. CONCLUSION: High CS NPY levels immediately after reperfusion correlate with microvascular dysfunction, greater myocardial injury, and reduced ejection fraction 6 months after STEMI. NPY constricts the coronary microcirculation via the Y1 receptor, and antagonists may be a useful PPCI adjunct therapy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Herring N, Tapoulal N, Kalla M, et al. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J. 2019. PMID: 30859228. doi:10.1093/eurheartj/ehz115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。